Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple claims are not supported by the provided prescribing information excerpts (e.g., capsule strength/formulation, specific side-effect list, missed-dose guidance, and several interaction details). Some safety concepts are generally consistent (somnolence/anorexia/dizziness; metabolic acidosis/lower bicarbonate; kidney stones; serious skin reactions; dehydration-like/encephalopathy-like symptoms), but overall alignment is limited by substantial unsupported or unverified details and a mismatch between capsule-based claims and the provided label for ZONISADE oral suspension.
Category Scores
Accurate Statements
Zonisamide is an anti-seizure drug.
Section 1 (adjunctive therapy for partial-onset seizures) and Section 14 (adjunctive therapy for refractory partial-onset seizures).
Zonisamide is used to treat certain types of seizures.
Section 1 INDICATIONS AND USAGE: adjunctive therapy for partial-onset seizures in adults and pediatric patients 16 years and older.
Zonisamide can lower blood bicarbonate.
Section 5.8 Metabolic Acidosis: decreased serum bicarbonate below the normal reference range.
Zonisamide can increase the risk of metabolic changes.
Section 5.8 Metabolic Acidosis and Section 12.2 (may cause metabolic acidosis; related metabolic change).
Zonisamide can raise the risk of kidney stones.
Section 5.13 Kidney Stones: may cause kidney stones; Section 7.2 also links carbonic anhydrase inhibitor use with increased risk of kidney stones.
Zonisamide can cause severe allergic reactions with swelling of the face or throat and trouble breathing.
Section 5.4 DRESS/Multiorgan hypersensitivity (systemic hypersensitivity; discontinuation if alternative etiology cannot be established). Note: the excerpt provided does not explicitly mention facial/throat swelling or trouble breathing, so support is indirect.
Zonisamide can cause severe skin reactions.
Sections 5.2 Serious Skin Reactions and 5.1 Potentially Fatal Reactions to Sulfonamides (SJS/TEN, etc.).
Zonisamide can affect alertness.
Section 5.11 Cognitive/Neuropsychiatric Adverse Reactions includes somnolence/fatigue; Section 6.1 includes somnolence.
People should use caution with driving or operating machinery until they know how zonisamide affects them.
Indirectly supported via somnolence/fatigue and CNS adverse reactions (Section 5.11; Section 6.1). Exact driving guidance not present in provided excerpts.
People should tell their prescriber and pharmacist about all medicines taken, including over-the-counter products and supplements, so interactions can be checked.
Not explicitly present in provided excerpts; interactions sections list drug classes and monitoring/dose adjustment, but the “tell prescriber/pharmacist about all medicines including OTC/supplements” wording is not included.
Unsupported Statements
Zonisamide 50 mg capsules are prescription medicine containing zonisamide at a strength of 50 milligrams per capsule.
Provided label excerpt is for ZONISADE (zonisamide) oral suspension (Section 3 shows 100 mg/5 mL). No capsule 50 mg strength information is provided.
Zonisamide is most commonly used as an add-on therapy for partial-onset seizures.
Label states it is indicated as adjunctive therapy for partial-onset seizures (Section 1; Section 14) but does not support “most commonly used.”
Dosing depends on the condition and the clinician’s titration plan.
Label provides specific recommended initial dose and titration schedule, but does not state “depends on the condition” or that dosing depends on “clinician’s titration plan” in that wording.
In practice, zonisamide dosing often starts low and increases gradually to reduce side effects and improve tolerance.
Label gives a titration schedule based on clinical response and tolerability (Section 2.2), but does not support the additional rationale wording (“often,” “reduce side effects and improve tolerance”).
Zonisamide should be taken exactly as prescribed.
No such general instruction appears in provided excerpts.
Zonisamide capsules are typically swallowed whole with water.
The provided label excerpts describe oral suspension administration (Section 3; Section 2.3 includes shaking and measuring; not swallowing capsules).
If a dose of zonisamide is missed, the patient should follow the instructions given by the prescriber rather than doubling up.
No missed-dose/doubling guidance appears in provided excerpts.
Common side effects of zonisamide include sleepiness or dizziness.
Label lists somnolence and dizziness among the most common adverse reactions (Section 6.1), but the statement’s “sleepiness or dizziness” framing is not exactly the label language; however it is largely consistent. Still, the excerpt does not explicitly use “common” or “sleepiness” phrasing. (Flagged as unsupported due to requirement to rely on excerpt text.)
Common side effects of zonisamide include loss of appetite.
Label lists anorexia (loss of appetite) among common adverse reactions (Section 6.1), but the exact “loss of appetite” wording is not used in the excerpt.
Common side effects of zonisamide include nausea.
Nausea is not listed in the provided “most common adverse reactions” excerpt (Section 6.1).
Common side effects of zonisamide include vomiting.
Vomiting is not listed in the provided “most common adverse reactions” excerpt (Section 6.1). Vomiting is referenced in hyperammonemia/encephalopathy symptom examples (Section 5.12), but not as a common adverse reaction.
Common side effects of zonisamide include weight loss.
Weight loss is not listed in the provided “most common adverse reactions” excerpt (Section 6.1).
A severe or persistent symptom after taking zonisamide warrants contacting the prescriber promptly.
No explicit general “contact prescriber promptly” instruction appears in provided excerpts.
Zonisamide can cause signs of dehydration such as marked weakness and confusion.
Provided excerpts discuss oligohidrosis/hyperthermia monitoring in pediatric patients and hyperammonemia/encephalopathy signs such as change in mental status, vomiting, or lethargy (Section 5.12), but “dehydration” and the specific “marked weakness and confusion” phrasing are not explicitly supported.
Zonisamide can cause symptoms suggestive of kidney stones, including severe flank pain and blood in urine.
Label confirms kidney stones may occur (Section 5.13) but provided excerpts do not list flank pain or hematuria.
Clinicians may switch between different zonisamide capsule strengths to match the required total daily dose.
Provided label excerpts do not discuss switching between capsule strengths; moreover, provided formulation is oral suspension (Section 3).
Substitution between zonisamide formulations should be done only with clinician/pharmacist guidance to maintain the same total daily dosing and titration schedule.
No formulation substitution/titration equivalence guidance is present in provided excerpts.
Zonisamide can interact with other medicines, including some anti-seizure drugs.
Provided interaction excerpts specify CNS depressants, other carbonic anhydrase inhibitors, and CYP3A4 inducers (Sections 7.1–7.3). The phrase “including some anti-seizure drugs” is not supported by the provided excerpts.
Zonisamide can interact with other drugs that affect liver metabolism.
Provided label excerpts discuss CYP3A4 inducers and monitoring/dose adjustment (Section 7.3), but “affect liver metabolism” is not the label wording; “liver metabolism” is not explicitly stated in the excerpt.
Extra caution may be needed with zonisamide for people with a history of kidney stones.
Label confirms kidney stones may occur (Section 5.13) and dose/treatment considerations in metabolic acidosis/renal function, but provided excerpts do not specify extra caution for history of kidney stones.
Extra caution may be needed with zonisamide for people with kidney disease.
Label provides specific avoidance in renal failure (estimated GFR < 50 mL/min) and monitoring/discontinuation in acute renal failure or sustained creatinine/BUN increase (Section 8.6). The general “extra caution for kidney disease” is not explicitly stated.
Extra caution may be needed with zonisamide for people with conditions that increase dehydration risk.
Provided excerpts discuss oligohidrosis and hyperthermia monitoring in pediatric patients (Section 5.5) and metabolic acidosis; dehydration-risk conditions are not explicitly described.
For pregnancy, planning pregnancy, or breastfeeding, zonisamide should be discussed with a neurologist or prescribing clinician to balance benefits and risks for the individual situation.
Label excerpt provides contraception counseling and fetal harm risk discussion (Section 5.10 and Section 8.1) but does not include “planning pregnancy” or “breastfeeding” or the instruction to consult a neurologist/prescribing clinician to “balance benefits and risks.”
Zonisamide is widely available as a generic in many markets.
No generic availability statement appears in provided label excerpts.
The 50 mg capsule strength is commonly used for dosing flexibility.
Provided label excerpts provide suspension strength (100 mg/5 mL) and do not mention 50 mg capsules or “dosing flexibility.”
A standard prescription label for zonisamide 50 mg capsule usually includes the dose strength (50 mg), the dosing schedule (number of capsules per day and timing), and the number of capsules dispensed.
No prescribing-label content guidance is present; additionally, provided label excerpts concern oral suspension, not 50 mg capsules.
The exact zonisamide regimen is individualized.
Label excerpt specifies recommended initial dosage and titration based on clinical response and tolerability (Section 2.2), but does not use the “exact regimen is individualized” phrasing.
Contradictions
Low
AI Statement
Zonisamide capsules are typically swallowed whole with water.
Label Reference
Provided label excerpts for ZONISADE describe oral suspension with shaking and accurate measuring (Sections 2.3 and 3). No capsule swallowing instructions are provided.
Low
AI Statement
Zonisamide 50 mg capsules... containing zonisamide at a strength of 50 milligrams per capsule.
Label Reference
Section 3 DOSAGE FORMS AND STRENGTHS provides oral suspension strength (100 mg/5 mL) and does not provide 50 mg capsule strength.
Important Omissions
No mention of the specific contraindication: hypersensitivity to sulfonamides or zonisamide (Section 4).
Importance:
Moderate
No mention of key warnings/precautions included in the excerpts, such as metabolic acidosis monitoring (baseline and periodic serum bicarbonate) and potential need for dose reduction/discontinuation (Section 2.1 and Section 5.8).
Importance:
Moderate
No mention of avoiding use in renal failure (estimated GFR < 50 mL/min) and discontinuation in acute renal failure/sustained creatinine/BUN increases (Section 8.6).
Importance:
Moderate
No mention of the warning for DRESS/multi-organ hypersensitivity discontinuation if alternative etiology cannot be established (Section 5.4) and serious skin reaction discontinuation at first sign of rash (Section 5.2).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant items are partially supported (metabolic acidosis/bicarbonate decrease; kidney stones; serious skin reactions; CNS-related somnolence). However, notable mismatches and unsupported specifics (capsules and 50 mg strength despite provided suspension label; missed-dose guidance; detailed symptom lists; and interaction generalizations) reduce reliability and could lead to inaccurate patient-facing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Mismatch between capsule-based content and the provided FDA label excerpts for ZONISADE oral suspension, plus multiple unsupported or insufficiently supported patient instructions and safety/interaction specifics.
Suggested Improvement
Restrict claims to information explicitly present in the provided label excerpts (use oral suspension terminology and strengths, align adverse reactions to the label list, remove capsule/50 mg-specific statements, and avoid adding symptom or interaction details not included in the excerpts). Include key on-label monitoring and avoidance guidance from Sections 2.1, 5.8, and 8.6.